Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: Results of North Central Cancer Treatment Group protocol N0177

International Journal of Radiation Oncology Biology Physics

Volumn 65, Issue 4, 2006, Pages 1192-1199

  Krishnan, Sunil ^a   Brown, Paul D ^a   Ballman, Karla V ^a   Fiveash, John B ^b   Uhm, Joon H ^a   Giannini, Caterina ^a   Jaeckle, Kurt A ^c   Geoffroy, Francois J ^d   Nabors, L Burt ^a   Buckner, Jan C ^a  

^a Mayo Clinic   (United States)

^b The University of Alabama at Birmingham   (United States)

^c MAYO CLINIC   (United States)

^d Oncology/Hematology Associates   (United States)

Author keywords

Erlotonib; Glioblastoma multiforme; Radiation therapy

Indexed keywords

BIOPSY; ENZYMES; TOXICITY; TUMORS;

ENZYME-INDUCING ANTICONVULSANTS (EIACS); ERLOTONIB; GLIOBLASTOMA MULTIFORME (GBM); MAXIMUM TOLERATED DOSE (MTD);

RADIOTHERAPY;

ANTICONVULSIVE AGENT; CORTICOSTEROID; ENZYME INDUCING AGENT; ERLOTINIB;

ACUTE HEART INFARCTION; ADULT; AGED; ALOPECIA; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DESQUAMATION; DETERIORATION; DIARRHEA; DOSE CALCULATION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG SCREENING; DRUG TOLERABILITY; FATIGUE; FEMALE; FOLLOW UP; GLIOBLASTOMA; HUMAN; INTERSTITIAL PNEUMONIA; MAINTENANCE THERAPY; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DERMATITIS; RADIATION DOSE; STOMATITIS; STRATIFICATION; SURVIVAL TIME; THROMBOCYTOPENIA; TUMOR BIOPSY; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; QUINAZOLINES; RADIOTHERAPY DOSAGE; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 33745183568     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2006.01.018     Document Type: Article

References (47)

1. DeAngelis L.M. Brain tumors. N Engl J Med 344 (2001) 114-123
2. Fine H.A., Dear K.B., Loeffler J.S., et al. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71 (1993) 2585-2597
3. Stewart L.A. Chemotherapy in adult high-grade glioma. A systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359 (2002) 1011-1018
4. Libermann T.A., Nusbaum H.R., Razon N., et al. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 313 (1985) 144-147
5. Frederick L., Wang X.Y., Eley G., et al. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 60 (2000) 1383-1387
6. Wong A.J., Bigner S.H., Bigner D.D., et al. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci USA 84 (1987) 6899-6903
7. Feldkamp M.M., Lau N., and Guha A. Signal transduction pathways and their relevance in human astrocytomas. J Neurooncol 35 (1997) 223-248
8. Sugawa N., Yamamoto K., Ueda S., et al. Function of aberrant EGFR in malignant gliomas. Brain Tumor Pathol 15 (1998) 53-57
9. Berens M.E., Rief M.D., Shapiro J.R., et al. Proliferation and motility responses of primary and recurrent gliomas related to changes in epidermal growth factor receptor expression. J Neuro-oncol 27 (1996) 11-22
10. Lund-Johansen M., Bjerkvig R., Humphrey P.A., et al. Effect of epidermal growth factor on glioma cell growth, migration, and invasion in vitro. Cancer Res 50 (1990) 6039-6044
11. Holland E.C., Celestino J., Dai C., et al. Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat Genet 25 (2000) 55-57
12. Holland E.C., Hively W.P., DePinho R.A., et al. A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice. Genes Dev 12 (1998) 3675-3685
13. Rich J.N., Reardon D.A., Peery T., et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 22 (2004) 133-142
14. Prados M.D., Lamborn K.R., Chang S., et al. Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neuro-oncol 8 (2006) 67-78
15. Uhm J.H., Ballman K.V., Giannini C., et al. Phase II study of ZD1839 in patients with newly diagnosed grade 4 astrocytoma. J Clin Oncol 22 Suppl (2004) 505
16. Raizer J., Abrey L., Wen P., et al. Phase 1 trial of OSI-774 (tarceva) in patients with recurrent malignant gliomas on enzyme-inducing anti-convulsants. A North American Brain Tumor Consortium Trial. Neuro-oncol 7 (2005) 320
17. Lieberman F.S., Cloughesy T., Fine H., et al. NABTC phase I/II study of ZD-1839 for recurrent malignant gliomas and unresectable meningiomas. Proc Am Soc Clin Oncol 22 Suppl (2004) 1510
18. Vogelbaum M.A., Goldlust S., and Kanner A. The EGFR tyrosine kinase inhibitor tarceva (OSI-774) shows activity against both wild-type and mutant EGFR function. Neuro-oncology 5 (2003) ET-47
19. Yung A., Vredenburgh J., Cloughesy T., et al. Erlotinib HCl for glioblastoma multiforme in first relapse, a phase II trial. J Clin Oncol 22 Suppl (2004) 1555
20. Schmidt-Ullrich R.K., Mikkelsen R.B., Dent P., et al. Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene 15 (1997) 1191-1197
21. Dent P., Reardon D.B., Park J.S., et al. Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. Mol Biol Cell 10 (1999) 2493-2506
22. Goldkorn T., Balaban N., Shannon M., et al. EGF receptor phosphorylation is affected by ionizing radiation. Biochim Biophys Acta 1358 (1997) 289-299
23. Lammering G., Valerie K., Lin P.S., et al. Radiosensitization of malignant glioma cells through overexpression of dominant-negative epidermal growth factor receptor. Clin Cancer Res 7 (2001) 682-690
24. Huang S.M., Bock J.M., and Harari P.M. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 59 (1999) 1935-1940
25. Huang S.M., and Harari P.M. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas. Inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 6 (2000) 2166-2174
26. Krishnan S., Rao R.D., James C.D., et al. Combination of epidermal growth factor receptor targeted therapy with radiation therapy for malignant gliomas. Front Biosci 8 (2003) e1-e13
27. Barker II F.G., Simmons M.L., Chang S.M., et al. EGFR overexpression and radiation response in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 51 (2001) 410-418
28. Han Y., Caday C.G., Nanda A., et al. Tyrphostin AG 1478 preferentially inhibits human glioma cells expressing truncated rather than wild-type epidermal growth factor receptors. Cancer Res 56 (1996) 3859-3861
29. Wild-Bode C., Weller M., Rimner A., et al. Sublethal irradiation promotes migration and invasiveness of glioma cells. Implications for radiotherapy of human glioblastoma. Cancer Res 61 (2001) 2744-2750
30. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Eng J Med 352 (2005) 987-996
31. Kaplan E., and Meier P. Non-parametric estimation for incomplete observations. J Am Stat Ass 53 (1958) 457-481
32. Peto R., and Peto J. Asymptotically efficient rank invariant procedures (with discussion). J Royal Stat Soc 135 (1972) 185-207
33. Perez-Soler R., Delord J.P., Halpern A., et al. HER1/EGFR inhibitor-associated rash. Future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist 10 (2005) 345-356
34. Rich J.N., Reardon D.A., Peery T., et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 22 (2004) 133-142
35. Rainov N.G., Dobberstein K.U., Bahn H., et al. Prognostic factors in malignant glioma. Influence of the overexpression of oncogene and tumor-suppressor gene products on survival. J Neuro-oncol 35 (1997) 13-28
36. Zhu A., Shaeffer J., Leslie S., et al. Epidermal growth factor receptor. An independent predictor of survival in astrocytic tumors given definitive irradiation. Int J Radiat Oncol Biol Phys 34 (1996) 809-815
37. Chakravarti A., Seiferheld W., Tu X., et al. Immunohistochemically determined total epidermal growth factor receptor levels not of prognostic value in newly diagnosed glioblastoma multiforme. Report from the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 62 (2005) 318-327
38. Etienne M.C., Formento J.L., Lebrun-Frenay C., et al. Epidermal growth factor receptor and labeling index are independent prognostic factors in glial tumor outcome. Clin Cancer Res 4 (1998) 2383-2390
39. Simmons M.L., Lamborn K.R., Takahashi M., et al. Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. Cancer Res 61 (2001) 1122-1128
40. Bouvier-Labit C., Chinot O., Ochi C., et al. Prognostic significance of Ki67, p53 and epidermal growth factor receptor immunostaining in human glioblastomas. Neuropathol Appl Neurobiol 24 (1998) 381-388
41. Leenstra S., Oskam N.T., Bijleveld E.H., et al. Genetic sub-types of human malignant astrocytoma correlate with survival. Int J Cancer 79 (1998) 159-165
42. Shinojima N., Tada K., Shiraishi S., et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 63 (2003) 6962-6970
43. Smith J.S., Tachibana I., Passe S.M., et al. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 93 (2001) 1246-1256
44. Arslantas A., Artan S., Oner U., et al. The importance of genomic copy number changes in the prognosis of glioblastoma multiforme. Neurosurg Rev 27 (2004) 58-64
45. Haas-Kogan D.A., Prados M.D., Tihan T., et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 97 (2005) 880-887
46. Mellinghoff I.K., Wang M.Y., Vivianco I., et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353 (2005) 2012-2024
47. Lassman A.B., Rossi M.R., Razier J.R., et al. Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors. Tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clin Cancer Res 11 (2005) 7841-7850